Monoclonal antibody-based therapies for hematologic malignancies

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Monoclonal antibody (MoAb) therapies have evolved significantly over the past two decades.
• These therapies are increasingly important in treating hematologic malignancies.

Purpose of the Study:

• To review recent advances in MoAb development and their clinical applications.
• To discuss the evolving roles of MoAb-based therapies in hematologic malignancies.

Main Methods:

• A comprehensive literature search of MEDLINE and CANCERLIT databases was performed.
• Bibliographies of identified articles were reviewed to find additional relevant publications.

Main Results:

• Three main categories of MoAb therapies have emerged: unconjugated MoAbs, immunotoxin-conjugated MoAbs (ITs), and radionuclide-conjugated MoAbs (RICs).
• Each category presents unique advantages and challenges regarding toxicity, efficacy, and clinical applicability.
• Current challenges include identifying optimal target antigens, overcoming limited penetration in bulk disease, and determining ideal clinical settings, such as minimal residual disease or combination therapy.

Conclusions:

• MoAb-based therapies represent a promising frontier for treating hematologic malignancies.
• Further research is essential to optimize the development and application of these novel treatments.